So far, the only study examining the efficacy and safety of tisa-cel in the treatment of lymphomas conducted in the pediatric population with CD19+ R/R B-cell non-Hodgkin’s lymphoma was the BIANCA study completed in 2023. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.